

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Non-Preferred High Potency (Groups 2 and 3) Topical Corticosteroids

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comment	Quantity Limit
Amcinonide 0.1% ointment/lotion	Preferred	May be subject to quantity limit
Augmented betamethasone dipropionate 0.05% cream		
Betamethasone valerate 0.1% ointment		
Diflorasone diacetate 0.05% cream		
Fluocinonide-E 0.05% cream		
Fluticasone propionate 0.025% ointment		
Triamcinolone 0.5% cream/ointment		
Amcinonide 0.1% cream	Non-Preferred	
Apexicon E 0.05% cream		
Betamethasone dipropionate 0.05% cream/ointment		
Betamethasone valerate 0.12% foam		
Bryhali 0.1% lotion		
Desoximetasone 0.25% cream/ointment/spray; 0.05% cream/gel/ointment		
Diflorasone diacetate 0.05% ointment		
Diprolene AF 0.05% cream		
Fluocinonide 0.05% cream/gel/ointment/solution		
Halocinonide 0.1% cream/ointment		
Halog 0.1% cream/ointment		
Impoyz 0.025% cream		
Luxiq 0.12% foam		

CRX-ALL-0569-20

PAGE 1 of 3 07/17/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Psorcon 0.05% cream	
Topicort 0.25% cream/ointment/spray; 0.05% cream/gel	
Triderm 0.5% cream	

APPROVAL CRITERIA

Requests for a non-preferred high potency topical corticosteroid may be approved when the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to two preferred high potency topical corticosteroids; **OR**
- II. The preferred agents are not FDA-approved for the prescribed indication and the requested non-preferred agent is; **OR**
- III. The preferred agents are not acceptable due to concomitant clinical situations, including but not limited to the following:
 - A. Individual requires an alternate dosage form; **OR**
 - B. Individual has a confirmed hypersensitivity to preferred agent(s) or class of agents.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 3, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. *Curr Opin Allergy Clin Immunol* 2010; 10:273.

PAGE 2 of 3 07/17/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

6. Goldstein BG, Goldstein AO. Topical corticosteroids: Use and adverse effects. [Comparison of representative topical corticosteroid preparations (classified according to the US system)]. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <https://www.uptodate.com> (Accessed on January 15, 2020.)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.